Report Code: A03303 | Pages: 193 | ||
Tables: 118 | Charts: 39 |
|
Global filgrastim market was valued at $ 562.50 million in 2020 and is projected to reach $745.90 million by 2030 registering a CAGR of 2.80% from 2021 to 2030. Filgrastim is a recombinant DNA-derived granulocyte colony stimulating factor (G-CSF) that is commonly used to treat low blood neutrophils. It's also commonly employed in cases where lukapheresis is associated with an increase in white blood cells. Filgrastim has a number of side effects, including joint discomfort, chest pain, hair loss, and vomiting.
Filgrastim is a recombinant version of the naturally occurring G-CSF that stimulates neutrophil production. It was licensed for the treatment of low blood neutrophils in the U.S. in 1991. The World Health Organization (WHO) declared Filgrastim in the List of Essential Medicines as safe and most effective medicine. Filgrastim was first discovered by Amgen, Inc. and sold under the brand name Neupogen. Large number of biosimilar companies are engaged in the manufacture and marketing of Filgrastim across the world. Filgrastim costs around $200 in the U.S, around 50 Euro in the UK, and $100 in developing countries.
Factors such as increase in prevalence of various diseases and surge igeriatric population drives the filgrastim market growth. Furthermore, increase in pressure to decrease healthcare expenditure and surge in demand for filgrastim, due to its cost effectiveness is anticipated to boost the growth of this market. In addition, surge in demand for biosimilars in the treatment of neutropenia further impede the market growth. However, common adverse effects of filgrastim include joint pain, chest pain, hair loss, and vomiting hinder the market growth. Conversely, increase in investing extensively in R&D activities for the development of effective and innovative biosimilars will further provide opportunities for the market.
Moreover, this medication is used to treat neutropenia, a condition that occurs after bone marrow transplantation and chemotherapy. It's been used to treat a variety of malignancies as a supportive therapy. In the recent decade, there has been a major growth in cancer prevention in industrialized countries, as well as government-led campaigns to raise awareness of early treatment. These reasons are projected to propel the worldwide Filgrastim market forward. Approved biosimilars such as Grafeel, Colstim, Neukine, and Filcad, which are much cheaper and readily available in developing countries, are expected to fuel the growth of the global Filgrastim market.
The outbreak of COVID-19 has disrupted workflows in the healthcare sector across the globe. The disease has forced a number of industries to shut their doors temporarily, including several sub-domains of healthcare. The filgrastim market size is expected to be negatively impacted by the COVID-19 situation. With the majority of countries suffering from the impact of COVID-19, many countries are looking for a way to cure COVID-19. The pandemic has had a serious and disruptive effect on oncology clinical trials and treatment, with both immediate and delayed consequences. According to a study conducted by the Cancer Research UK in July 2020, one in three cancer patients have confirmed that their treatment has been impacted by the effects of COVID-19. The short-term effects include staff and resources being reassigned to deal with COVID patients. In the longer term, trials testing treatments for COVID-19 have been ordered. A sharp reduction in recruitment to ongoing trials and a delay in the planned launch of new oncology studies is expected to negatively impact the filgrastim market.
The global filgrastim market is segmented on the basis of drug type, distribution channel, indication and region. On the basis of drug type, it is further classified into biologic and biosimilar. By distribution channel, it is divided into hospital pharmacies, retail pharmacies and online pharmacies. Based on indication, it is categorized into chemotherapy induced neutropenia, chronic neutropenia and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By drug type, the biosimilars segment is expected to expand at a higher growth rate due to low cost and easy availability in developing countries. Furthermore, ongoing biosimilars research and strong pipeline drugs are expected to boost the growth of the global market during the forecast period.
Based on distribution channel, the global filgrastim market can be categorized into hospital pharmacies, retail pharmacies, and online pharmacies. High demand for filgrastim in hospitals across the globe is projected to propel the hospital pharmacies segment from 2020 to 2030.
Europe is projected to account for a major share of the global filgrastim market during the forecast period. The market in the region is anticipated to grow in the future, owing to developed health care infrastructure and favorable reimbursement policies, rise in prevalence of infectious diseases and cancer, and the availability of research grants and funding are propelling the market growth in Europe.
The key market players profiled in the report include Abbott Laboratories, Amgen, Apotex, Cadila Pharmaceuticals, Dr. Reddy's Laboratories, Kirin Holding (Kyowa Kirin), Novartis, Pfizer, Teva Pharmaceutical Industries Ltd. and Toksöz Group (Arven).
Filgrastim Market Research Study Key Benefits
Key Market Segments
By Drug Type
By Distribution Channel
By Indication
By Region
Leading Players of Filgrastim Market
Filgrastim Market Report Highlights
Aspects | Details |
---|---|
By DRUG TYPE |
|
By DISTRIBUTION CHANNEL |
|
By INDICATION |
|
By Region |
|
Key Market Players | ABBOTT LABORATORIES, AMGEN INC., KIRIN HOLDINGS, TOKSÖZ GROUP., NOVARTIS AG, TEVA PHARMACEUTICAL INDUSTRIES LTD., DR. REDDY’S LABORATORIES LIMITED, ZYDUS CADILLA, APOTEX INC., PFIZER INC. |
Loading Table Of Content...
Filgrastim market growth includes increase in pressure to decrease healthcare expenditure and surge in demand for filgrastim due to its cost effectiveness is anticipated to boost the growth of this market. In addition, surge in demand for biosimilars in the treatment of neutropenia further impede the market growth. However, common adverse effects of filgrastim include joint pain, chest pain, hair loss, and vomiting hinder the market growth. On the other hand, increase in investing extensively in R&D activities for the development of effective and innovative biosimilars will further provide opportunities for the market.
Europe is projected to account for a major share of the global filgrastim market during the forecast period. The market in the region is anticipated to witness growth in the future, owing to developed healthcare infrastructure and favorable reimbursement policies, rise in prevalence of infectious diseases and cancer, and the availability of research grants and funding are propelling the market growth in Europe. Furthermore, increase in number of cancer patients, particularly in developing countries such as China and India, is one of the key factors expected to propel the global filgrastim market during the forecast period.
A. The total market value of Filgrastim market is $562.5 million in 2020.
A. The forcast period for Filgrastim market is 2021 to 2030
A. The market value of Filgrastim market in 2021 is $582.2 million.
A. The base year is 2020 in Filgrastim market
A. Top companies such asAbbott Laboratories, Amgen, Apotex, Cadila Pharmaceuticals, Dr. Reddy's Laboratories, Kirin Holding (Kyowa Kirin), Novartis, Pfizer, Teva Pharmaceutical Industries Ltd and Toksöz Group (Arven) held a high market position in 2020.
A. Biosimilars segment is expected to expand at a higher growth rate due to low cost and easy availability in developing countries. Furthermore, ongoing biosimilars research and strong pipeline drugs are likely expected to boost the growth of the global market during the forecast period.
A. Increase in prevalence of various diseases and surge in geriatric population drives the filgrastim market growth. Furthermore, increase in pressure to decrease healthcare expenditure and surge in demand for filgrastim, due to its cost effectiveness is anticipated to boost the growth of this market
A. Europe is projected to account for a major share of the global filgrastim market during the forecast period. The market in the region is anticipated to grow in the future, owing to developed health care infrastructure and favorable reimbursement policies, rise in prevalence of infectious diseases and cancer, and the availability of research grants and funding are propelling the market growth in North America.
Start reading instantly.
This Report and over 71,323+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time for readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers